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The majority of patients undergoing hemodialysis have anemia due to decreased production 
of erythropoietin. This condition is referred to as renal anemia, and is a type of normocytic 
and normochromic anemia. Renal anemia contributes to a worsening of quality of life (QOL) 
and has a poor prognosis for survival. 
Clinical use of erythropoiesis-stimulating agents (ESAs) has markedly improved the QOL 
and prognosis for survival of hemodialysis patients. ESA is commonly used for treatment of 
renal anemia, but some hemodialysis patients subsequently develop macrocytic and 
hypochromic anemia that is not responsive to vitamin B12 and folic acids (Ogura et al., 
2007). Macrocytic and hypochromic anemia after ESA treatment is also common in elderly 
hemodialysis patients (Murata, 1998). However, the mechanism underlying ESA induction 
of these changes in erythropoiesis is unknown. 
The correlation between renal anemia and ischemic heart disease, which is referred to as 
cardiorenal anemia syndrome (CARS) (Silverberg, 2003), suggests that treatment of anemia 
may also suppress cardiovascular events. However, the results of the Correction of 
Hemoglobin and Outcome in Renal Insufficiency (CHOIR) study showed that patients with 
a high hemoglobin level in stage III-IV chronic kidney disease (CKD) after use of large doses 
of ESA have a poor prognosis for cardiovascular complications (Singh et al., 2006). Also, in a 
meta-analysis, Phrommintikul et al. reported an increased incidence of cerebrovascular 
disease in patients treated with ESAs at a high dose, with the incidence not related to the 
hemoglobin value (Phrommintikul et al., 2007). Recently, the results of a randomized control 
study (Trial to Reduce cardiovascular Events with Aranesp Therapy: TREAT) in diabetic 
CKD patients showed that darbepoetin did not have an inhibitory effect on the progression 
of renal dysfunction and the new onset of cardiovascular events (Pfeffer et al., 2009). Based 
on the results of the TREAT trial, it was concluded that the cause of the poor prognosis in 
patients receiving large doses of ESA is an increased incidence of cerebrovascular disorders. 
However, analyses in the CHOIR and TREAT trials were based on ESA treatment with 
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different intervals of administration, and there has not been sufficient investigation of the 
effects of different types of ESA on prognosis. Therefore, it remains unclear whether 
treatment of anemia leads to suppression of cardiovascular events. 
2. Effects of erythropoiesis stimulating agents on hematopoietic response 
and cerebrovascular disorders 
The mechanism through which large doses of ESA promote the onset of cerebrovascular 
disorders has not been fully elucidated, and it is unclear whether there is a direct causal 
relationship. Therefore, in this study, we evaluated the effects of different types of ESA on 
erythropoiesis, investigated the factors responsible for determining the poor response to 
ESAs, and determined the incidence of cerebrovascular disorders with different types of 
ESA. 
2.1 Effects of different types of ESA on hematopoietic response  
The subjects were 78 maintenance hemodialysis patients with ESRD (40 men and 38 women; 
age 63.9 ± 9.8 (mean ± SD) years old, range: 32-82 years old) who were treated at our clinic 
(HD duration 13.4 ± 9.8 years, range: 2-35 years). Inclusion in the study required that 
patients were taking epoetin for treatment of renal anemia and had no active inflammatory 
disease. The causes of ESRD were diabetes mellitus (n=20), chronic glomerulonephritis 
(n=42), renal sclerosis (n=5), IgA nephropathy (n=2), and unknown/uncertain (n=9). 
Patients were being treated twice or thrice weekly with standard bicarbonate dialysis with 
semisynthetic membranes (dialysis filter surface area 1.3-2.4 m2). The mean weekly HD 
duration was 10.3 ± 1.5 h. Dry weight was targeted in each case to achieve a normotensive 
edema-free state. The study protocol complied with the ethical guidelines of our institution 
and informed consent was obtained from each patient. 
The 78 patients were randomly divided into two groups in December 2008: those (N=30) 
who continued to take epoetin (epoetin group), and those (N=48) who switched to 
darbepoetin instead of epoetin (darbepoetin group). The dose of darbepoetin was 
determined using a ratio of 1:200 relative to the epoetin dose. In addition to a general 
physical examination and routine blood tests, the erythrocyte index, iron metabolism 
markers, normalized protein catabolic rate (nPCR) as a nutrition factor, and Kt/V as a 
dialysis efficacy factor were measured before dialysis every month for 1 year. Comparisons 
between the two groups were made using average values over 1 year. The doses of ESA and 
venous iron were modulated with the goal of maintaining hemoglobin (Hb) at 10-11 g/dL 
and ferritin at 100–200 ng/mL. 
The general characteristics of the study population are summarized in Table 1. There were 
no significant differences in baseline values between the epoetin and darbepoetin groups. 
Changes of parameters in the epoetin group are shown in Table 2. Ferritin, transferrin 
saturation (TSAT) and iron dose all decreased after one year, compared to the respective 
baseline values. There were no significant differences in the mean corpuscular volume 
(MCV) and the mean corpuscular hemoglobin concentration (MCHC) (Fig. 1). 
Changes of parameters in the darbepoetin group are shown in Table 3. The Ht value 
increased significantly and MCHC decreased significantly after one year, compared to the 
respective baseline values. The change from epoetin to darbepoetin resulted in a significant 
decrease in MCHC (Fig. 2). 
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Parameter Epoetin  (N=30) Darbepoetin (N=48) P-value 
Age (year) 62.3±10.9  (32-82） 65.0±9.8  (36-80） n. s. 
HD duration (year) 14.0±10.6  (2-35） 12.9±9.0  (2-34） n. s. 
Male / Female 12/ 18 28 / 20 n. s. 
Cause of CKD  
     Chronic 
glomerulonephritis
17 25  
     Diabetic nephropathy  7 13  
     Renal sclerosis 2 3  
     IgA nephropathy 1 1  
     Unknown 3 6  
Pre Hb (g/dl) 10.25±0.41 10.28±0.53 n. s. 
Pre Ht (%) 31.13±1.12 31.42±1.60 n. s. 
Pre MCV (fl) 98.01±5.23 96.90±3.09 n. s. 
Pre MCH (pg） 32.28±1.86 31.70±1.24 n. s. 
Pre MCHC (%) 32.93±0.51 32.71±0.45 n. s. 
Pre Ferritin (ng/ml) 151.4±91.3 152.6±35.3 n. s. 
Pre TSAT (%) 30.2±8.4 30.2±7.2 n. s. 
Pre Iron dose (mg/week) 10.8±10.0 15.5±6.2 n. s. 
Pre rHuEPO dose (IU/week) 4318±2219 3591±1792 n. s. 
Table 1. General characteristics of the 78 hemodialysis patients. 
 
Parameter Baseline After one year P-value 
Hb (g/dl) 10.28±0.53 10.21±0.35 n. s. 
Ht (%) 31.42±1.60 31.17±0.99 n. s. 
MCV (fl) 96.90±3.09 97.39±3.82 n. s. 
MCH (pg） 31.70±1.24 31.90±1.43 n. s. 
MCHC (%) 32.71±0.45 32.74±0.40 n. s. 
Ferritin (ng/ml) 152.6±35.3 128.3±40.6 p<0.05 
TSAT (%) 30.2±7.2 26.0±7.4 p<0.05 
Iron dose (mg/week) 15.5±6.2 8.1±6.1 p<0.01 
rHuEPO dose (IU/week) 3591±1792 3766±1942 n. s. 
Table 2. Changes of parameters in the epoetin group. 
 
Parameter Baseline After one year P-value 
Hb (g/dl) 10.25±0.41 10.23±0.49 n. s. 
Ht (%) 31.13±1.12 31.77±1.34 p<0.05 
MCV (fl) 98.01±5.23 98.60±5.92 n. s. 
MCH (pg) 32.28±1.86 31.75±2.13 n. s. 
MCHC (%) 32.93±0.51 32.18±0.59 p<0.001 
Ferritin (ng/ml) 151.4±91.3 136.0±63.4 n. s. 
TSAT (%) 30.2±8.4 28.3±9.2 n. s. 
Iron dose (mg/week) 10.8±10.0 12.8±7.9 n. s. 
rHuEPO dose (IU/week) 4318±2219 4131±3145 n. s. 
Table 3. Changes of parameters in the darbepoetin group (DA dose: 20.7±15.7 µg/week). 
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Fig. 2. Changes of annual mean values of MCV and MCHC in the darbepoetin group. 
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In this study, the change from epoetin to darbepoetin resulted in a significant increase in Ht 
and a significant decrease in MCHC, while continuation of epoetin did not change the 
erythrocyte index (EI). Since there were no significant differences in ferritin, TSAT and iron 
dose between the two groups, the changes of Ht and MCHC may have originated from the 
effect of darbepoetin. The increase of Ht and decrease of MCHC indicate macrocytic and 
hypochromic changes of erythrocytes. The mechanism of these changes induced by 
darbepoetin remains unknown. 
2.2 Factors responsible for determining a poor response to an ESA 
Next, the responsiveness to darbepoetin was evaluated by dividing the 48 patients in the 
darbepoetin group into two subgroups. The high dose (n=14) and low dose (n=34) 
subgroups comprised patients who required a DA dose of ≥60 µg/week and <60 
µg/week, respectively, during the follow-up period. The annual mean values of EI, iron 
metabolism markers, nPCR and Kt/V and the incidences of complications were compared 
between the two subgroups (Table 4). A higher rate of complication of hepatic cirrhosis 
was found in the high dose subgroup (p<0.02). There were no significant changes in Kt/V, 
nPCR and other parameters between the two subgroups. There was also no significant 






High dose subgroup 
   (DA≧60ug/week) P-value 
N 34 14  
Age  (year) 64.88±10.57 65.31±6.00 n. s. 
HD duration (year) 13.03±9.37 15.00±9.53 n. s. 
Sex (Male / Female) 19 / 15 11 / 3 n. s. 
Diabetes (%) 38.2 (13/34) 35.7 (5/14) n. s. 
Complication of liver cirrhosis (%) 2.9 (1/34) 28.5 (4/14) P<0.02 
Dry weight (kg) 50.48±8.33 53.35±7.84 n. s. 
HD time (hour) 4.02±0.23 4.44±0.46 n. s. 
Kt/V 1.53±0.17 1.58±0.22 n. s. 
nPCR (g/kg/day) 0.89±0.15 0.85±0.19 n. s. 
Alb (g/dL) 3.92±0.21 3.95±0.17 n. s. 
Hb (g/dL) 10.31±0.47 10.11±0.25 n. s. 
Ht (%) 32.05±1.19 31.48±0.58 n. s. 
MCH (pg) 31.57±1.90 32.63±1.29 n. s. 
MCV (fL) 98.16±5.20 101.60±4.02 n. s. 
MCHC (%) 32.16±0.66 32.12±0.37 n. s. 
TSAT (%) 29.19±9.27 30.31±7.12 n. s. 
Ferritin (ng/mL) 153.55±66.45 110.25±21.88 p<0.01 
CRP (mg/dL) 0.32±0.52 0.33±0.31 n. s. 
Iron dose (mg/week) 10.73±6.57 14.62±4.75 n.s. 
Average DA dose (µg/week) 13.53±5.19 33.77±16.95 p<0.02 
Table 4. Comparison of the high dose and low dose darbepoetin subgroups. 
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The required dose of darbepoetin was significantly higher for patients complicated with 
liver cirrhosis. Such patients were not excluded from the CHOIR or TREAT study, which 
suggests that this complication affects the prognosis of patients receiving a high dose of 
darbepoetin. In Japan, ESA hyporesponsiveness is defined as a failure of improvement of 
anemia with a darbepoetin dose of 60 µg/week or an epoetin dose of 9000 IU/week without 
iron deficiency (Tsubakihara et al., 2010). Insufficient dialysis, malnutrition, unclean 
dialysate, and drug effects have been suggested as causes of ESA hyporesponsiveness 
(Ifudu et al., 1996). In this study, there were no significant differences in any parameters 
except ferritin between the low dose and high dose darbepoetin subgroups. Since there was 
no difference in the given iron dose, the patients in the high dose subgroup might be 
exhibiting hyporesponsiveness to iron.    
2.3 Incidence of cerebrovascular events with different types of ESA 
Finally, the incidence of cerebrovascular events was evaluated in follow-up of onset of 
cerebrovascular disorders for another year (a total observation period of 2 years) in patients 
in both groups. The Kaplan-Meier method was used to analyze the incidence of 
cerebrovascular disorders from the beginning of the observation period (Fig. 3). There was 
no significant difference in cerebrovascular event-free survival between the epoetin and 
darbepoetin groups. Although no difference in the incidence of cerebrovascular events was 
found following the change from epoetin to darbepoetin, the incidence of cerebrovascular 
events showed a tendency to increase in the high dose darbepoetin subgroup. 
 
 
Fig. 3. A. Cerebrovascular event-free survival in the epoetin (EPO) and darbepoetin (DA) 
groups. B. Cerebrovascular event-free survival in the high dose and low dose darbepoetin 
subgroups. 
A random prospective study showed poor mortality and a high incidence of cardiovascular 
events in hemodialysis patients with high Hb compared to those with normal hematocrit 
(Besarab et al., 1998). Moreover, the results of secondary analysis in the CHOIR study 
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showed that patients in whom anemia did not improve with administration of large doses 
of ESA had a worsened prognosis compared to patients in whom anemia did improve with 
a low dose of ESA (Szczech et al., 2008). Thus, it is currently thought that a lower response 
to ESA (ESA hyporesponsiveness) results in a poor prognosis. In the current study, we 
found no significant difference in the incidence of cerebrovascular events over a two-year 
observation period between patients treated with epoetin and darbepoetin. However, a 
higher, although not significantly higher, incidence of cerebrovascular events was found in 
patients who received a high dose of darbepoetin. Collectively, these data suggest that 
particular care is needed in treatment of patients with ESA hyporesponsiveness. 
3. Conclusion 
The ESA dose was significantly higher for patients complicated with liver cirrhosis, who 
were not excluded from either the CHOIR or TREAT study. This suggests that this 
complication affects the prognosis of patients receiving a high dose of an ESA. We found no 
significant difference in the incidence of cerebrovascular events with epoetin and 
darbepoetin during a two-year observation period; however, epoetin and darbepoetin might 
have different effects on the hematopoietic response. 
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